Stable aqueous Pharmaceutical formulations comprising an Antibody anti PDL1. Methods for preparing such formulations and Methods of using such formulations.Claim 1: a stable aqueous Pharmaceutical formulation, characterized in that it comprises a monoclonal anti PDL1 at a concentration of 40 mg / ml to approximately 125 mg / ml, histidine acetate or SODIUM ACETATE at a concentration of approximately 15 mm Approximately 25 mm sucrose at a concentration of approximately 60 mm approximately 240 mmPolysorbate at a concentration of approximately 0.005% (W / V) to approximately 0.06% (W / V) and a pH of about 5.0 to about 6.3.Formulaciones farmacéuticas acuosas estables que comprenden un anticuerpo anti-PDL1. Métodos para preparar tales formulaciones y métodos de uso de tales formulaciones. Reivindicación 1: Una formulación farmacéutica acuosa estable, caracterizada porque comprende un anticuerpo monoclonal anti-PDL1 en una concentración de aproximadamente 40 mg/ml a aproximadamente 125 mg/ml, acetato de histidina o acetato de sodio en una concentración de aproximadamente 15 mM a aproximadamente 25 mM, sacarosa en una concentración de aproximadamente 60 mM a aproximadamente 240 mM, polisorbato en una concentración de aproximadamente 0,005% (p/v) a aproximadamente 0,06% (p/v) y un pH de aproximadamente 5,0 a aproximadamente 6,3.
